Amgen

We are all different, yet we have this in common: our mission to serve patients. This sense of shared purpose is key to our becoming one of the world’s leading biotechnology companies. It guides us as we continue to launch new medicines and reach millions of patients worldwide.

We live the mission.

We win together.

We thrive on continual challenge.

Our team of 27,000+ scientists and professionals worldwide bring distinct perspectives and experiences to all we do. We leverage our global talent to achieve together—to research, manufacture and deliver ever-better products and greater depth to our mission.

At Amgen, there is a strong correlation between our high level of diversity and performance. Because addressing issues with a wider range of perspectives and approaches leads to more creative problem-solving. Together, we’re transforming the promise of science and biotechnology into therapies that have the power to restore health.

Connect with us to explore how you can Win, Live, and Thrive at Amgen.

AWARDS

Corporate Headquarters
One Amgen Center Drive
Thousand Oaks, CA 91320

Tel: 805-447-1000

Visit website

Email Us

LIVE. WIN. THRIVE.

We know an idea—any idea—can blossom into a lifesaving treatment. That’s why we dare to ask the questions most people won’t. Join us in pushing biotechnology.

Join Us

Employee Testimonials

“Amgen fosters a culture of innovation, with a science-based risk approach, centered in the benefit of our patients and powered by the diversity of our staff.”

Jorge D.
Porcess Scientific Director
Juncos, PR
“Cultivate your curiosity and continue to learn at Amgen — grow daily and explore career opportunities that align with your competencies and motivation”

Fernando F.
Executive Director Plant Manager
Rhode Island, US
“Working at Amgen, as Specialist Quality Control gives me the opportunity to work with Amgen products in benefit of the patients. Using my knowledge in science and share my diversity with my peers, is the best experience I have as part of the Amgen family.”

Niria R.
Specialist Quality Control
Juncos, PR

Diversity and Inclusion
Benefits
Community Investment
Awards and Accolades

Serving patients across the globe requires a global team. We continue building a diverse workforce that reflects the needs of those they serve, bringing with them innovative ideas that can push biotechnology forward.

Learn More

We offer more than benefits. Our Total Rewards Program secures the long-term financial, physical and overall well-being of you and your family. Among leading biotechnology and pharmaceutical leaders, we stand among the very best.

Learn More

Through Amgen Volunteers, you can dedicate eight hours to participating organizations of your choice. This along with matching employee donations to charities and our diverse corporate giving initiatives are just some ways you can make meaningful contributions as a global citizen

Learn More

Amgen is proud of the achievements we have realized as a mission-driven team—particularly the accolades we have earned as an employer. You can find our teams named in respected lists including Forbes, Fast Company and more.

Learn More

NEWS

Business

The Future of Cancer Treatment Lies in Vaccines, Say These Pioneers

NEUVOGEN’s official strategy revolves around covering the entire immune system so that the tumor cannot perform an “immune escape”. Past immune priming efforts have fallen short because they focus on only a handful of important targets that some tumor cells may not express, thereby allowing them to escape the therapy’s boundaries.

January 20, 2021

6 min read

Heather McKenzie

FDA

FDA Action Alert: Merck, Aurinia and Amgen

After a start-of-the-year lull, activities at the U.S. Food and Drug Administration are starting to pick up. Here’s a look.

January 15, 2021

3 min read

Mark Terry

Business

Amgen Inks $240 Million Autoimmune Deal with Tiny EVOQ Therapeutics

The two companies will work together to use dendritic cells to develop immune tolerance.

January 13, 2021

2 min read

Mark Terry

Drug Development

Amgen-AstraZeneca Experimental Asthma Drug Surprisingly Flops in Phase III

An investigational asthma treatment, tezepelumab, under development by Amgen and AstraZeneca failed to reduce asthma patients’ dependence on corticosteroids.

December 22, 2020

2 min read

Alex Keown

Policy

Five Companies Earn Validation as FDA Recognizes New Breakthrough Therapies

Novartis’ Iptacopan isn’t the only drug to receive Breakthrough Therapy designation this week. Several other experimental treatments were also awarded the designation.

December 16, 2020

4 min read

Alex Keown

Policy

FDA Action Alert: MacroGenics and Amgen

As the year wraps up, there are still some PDUFA dates on the agency’s calendar. Read on for this week’s.

December 11, 2020

3 min read

Mark Terry

Drug Development

Amgen and AstraZeneca’s Tezepelumab Looking to Be First-in-Class Asthma Treatment

Amgen and AstraZeneca announced that their Phase III NAVIGATOR trial of Tezepelumab hit the primary endpoint in severe asthma.

November 10, 2020

3 min read

Mark Terry

FDA

FDA Action Alert: Supernus, Adamis, Alkermes, Amgen, BMS and Eiger

Here’s a look at some of the upcoming target action dates on the U.S. FDA’s calendar.

November 6, 2020

4 min read

Mark Terry

Drug Development

Bristol Myers’ Experimental Psoriasis Drug Beats Out Amgen’s Otezla in Phase III

“With limited oral therapeutic options available for psoriasis, there remains a significant need for safe and effective therapies,” said April Armstrong, associate dean and professor of dermatology at the University of Southern California.

November 3, 2020

3 min read

Mark Terry

JOBS